The European Commission (EC) has granted Galapagos’ investigational product GLPG1690 orphan drug designation for the treatment of patients with idiopathic pulmonary fibrosis (IPF). GLPG1690 is a selective autotaxin inhibitor that was demonstrated to have a favorable safety and tolerability profile in a Phase 1 study in healthy volunteers. Autotaxin plays an…
Long-term treatment of idiopathic pulmonary fibrosis (IPF) patients with Ofev (nintedanib) showed positive effects in keeping disease progression at bay, while inducing manageable side effects, Boehringer Ingelheim Pharmaceuticals announced. This finding comes from the INPULSIS-ON clinical trial  — an extension study of the INPULSIS trial — designed to assess the long-term effects of…
A new study suggests that metformin, a drug widely used to treat diabetes, can benefit people with idiopathic pulmonary fibrosis (IPF) by working to diminish lung fibrosis. The study, “Metformin Attenuates Lung Fibrosis Development Via NOX4 Suppression,” was published in the journal Respiratory Research by Nahoko Sato, MD, and…
Esbriet (pirfenidone) is as safe a treatment for idiopathic pulmonary fibrosis (IPF) in the long-term as it is already known to be from shorter term studies, data presented at the recent European Respiratory Society (ERS) International Congress 2016 showed. In addition, two other studies presented research highlights of the drug’s importance…
Treatment with Ofev (nintedanib) is associated with stabilization of lung function in patients with idiopathic pulmonary fibrosis (IPF) according to a study published in the scientific journal Respiration.
News Commentary In the absence of conclusive scientific data about the outcomes of stem cell therapy in people with serious and chronic diseases — from multiple sclerosis and Alzheimer’s to pulmonary fibrosis — the hundreds of clinics offering these therapies across the U.S., and the thousands worldwide, rely mainly on…
Musicians who play wind instruments are being warned of a potential hazard doctors have dubbed “bagpipe lung” — after a case study was published of a man who died of a lung condition known as hypersensitivity pneumonitis, thought to have been caused by the mold and fungi that thrived in the moist interior of a…
Boehringer Ingelheim recently held a second regional respiratory conference concerning the latest medical and scientific insights on the treatment and management of respiratory diseases — namely, pulmonary fibrosis, chronic obstructive pulmonary disease (COPD) and asthma. These conditions represent a major public health problem in developing countries, due to their high incidence, and their…
Physical inactivity and low blood-oxygen levels during periods of exercise predict poor survival in patients with idiopathic pulmonary fibrosis (IPF), according to researchers at the Rabin Medical Center in Israel. The study, “Physical Activity and Exertional Desaturation Are Associated with Mortality in Idiopathic Pulmonary Fibrosis,” published in the Journal of…
Researchers are one step closer to understanding the molecular mechanism of action of pirfenidone, the anti fibrotic drug for the treatment of pulmonary fibrosis. This may help improve the safety and efficacy of the drug, which is often used in very high doses to achieve therapeutic effectiveness, causing a range of adverse side effects.
Get regular updates to your inbox.
